Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study

References

• Adam JK, Rodeheaver TG. (2010). Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof. US Patent 20100183519
   Google Scholar
• Ahad A, Aqil M, Kohli K, et al. (2011). Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action. Drug Dev Ind Pharm 37:583–96
   PubMed Web of Science ®Google Scholar
• Ahuja A, Baboota S, Ali J, Mustafa G. (2011). Cyclodextrins as Potential Excipients in Pharmaceutical Formulations: Solubilizing and Stabilizing Effects. In: Erem Bilensoy, ed. Cyclodextrins in pharmaceutics, cosmetics, and biomedicine: current and future industrial applications. CH 2, 12-26; JOHN WILEY & SONS, Inc. DOI: 10.1002/9780470926819
   Google Scholar
• Cunningham J, Liversidge EM. (2005). Nanoparticulate compositions having a peptide as a surface stabilizer. US Patent 0238725
   Google Scholar
• Dixit A, Rajput S, Patel S. (2010). Preparation and Bioavailability Assessment of SMEDDS Containing Valsartan. AAPS Pharm Sci Tech 11:314–21
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, et al. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm 33:1332–9
   PubMed Web of Science ®Google Scholar
• Grau MJ, Kayser O, Muller RH. (2000). Nanosuspensions of poorly soluble drugs – reproducibility of small scale production. Int J Pharm 196:155–7
   PubMed Web of Science ®Google Scholar
• Hinrichs WL, Sanders NN, DeSmedt SC, et al. (2005). Inulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes. J Control Rel 103:465–79
   PubMed Web of Science ®Google Scholar
• Hinrichs WL, Mancenido FA, Sanders NN, et al. (2006). The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm 311:237–44
   PubMed Web of Science ®Google Scholar
• Keck CM, Muller RH. (2006). Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenisation. Eur J Pharm Biopharm, 62:3–16
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125:309–13
   Web of Science ®Google Scholar
• Liversidge GG, Cundy KC, Bishop JF, Czekai DA. (1992). Surface modified drug nanoparticles. United States Patent 5145684
   Google Scholar
• Ma Q, Sun H, Che E, et al. (2013). Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state. Int J Pharm 441:75–81
   PubMed Web of Science ®Google Scholar
• Mahajan P, Mahajan SC, Mishra DK. (2011). Valsartan release from sustained release matrix tablet and effect of cellulose derivatives. Int J Pharm Life Sci 2:521–30
   Google Scholar
• Moffat AC. (2011). Clark’s analysis of drugs and poisons. London: London Pharmaceutical Press
   Google Scholar
• Moschwitzer J, Muller R. (2007). Drug nanocrystals-the universal formulations approach for poorly soluble drugs. In: Thassu D, Deleers M, Pathak Y, eds. Nanoparticulate Drug Delivery System. Informa Healthcare. New York, 71–88
   Google Scholar
• Mujtaba A, Ali M, Kohli K. (2014). Statistical optimization and characterization of pH-independent extended-release drug delivery of cefpodoxime proxetil using Box–Behnken design. Chem Eng Res Des 92:156–65
   Web of Science ®Google Scholar
• Muller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int J Pharm 160:229–37
   Web of Science ®Google Scholar
• Nalawade P, Aware B, Dand N, et al. (2009). Solid state characterization of the inclusion complex of valsartan with methyl β-cyclodextrin. J Incl Phenomena Macro Chem 65:377–83
   Web of Science ®Google Scholar
• Park YJ, Lee HK, Im YB, et al. (2010). Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Arch Pharm Res 33:1235–40
   PubMed Web of Science ®Google Scholar
• Pawar VK, Singh Y, Meher JG, et al. (2014). Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery. J Control Release 23:51–66
   Web of Science ®Google Scholar
• Rukhman I, Flyaks E, Koltai T, Aronhime J. (2006). Polymorphs of valsartan. US Patent 20067105557
   Google Scholar
• Sharma A, Jain CP. (2010). Preparation and characterization of solid dispersions of Valsartan with Poloxamer 188. Der Pharmacia Lettre 2:54–63
   Google Scholar
• Speiser PP. (1998). Poorly soluble drugs: a challenge in drug delivery, In: Muller RH, Benita S, Bohm B, eds. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart, Germany: Medpharm Scientific Publishers, 15–28
   Google Scholar
• Verma S, Lan Y, Gokhale R, Burgess DJ. (2009). Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 377:185–98
   PubMed Web of Science ®Google Scholar
• Zarghi A, Shafaati A, Foroutan SM, et al. (2008). Rapid quantification of valsartan in human plasma by HPLC using monolithic column. Pharm Sci 76:439–50
   Google Scholar
• Zhang D, Tan T, Gao L, et al. (2007). Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 33:569–75
   PubMed Web of Science ®Google Scholar